Details for Patent: 8,420,056

Which drugs does patent 8,420,056 protect, and when does it expire?

Patent 8,420,056 protects NUCYNTA ER and is included in one NDA.

This patent has one hundred and seventy-seven patent family members in thirty-one countries.

Summary for Patent: 8,420,056

Title:	Abuse-proofed dosage form
Abstract:	The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form.
Inventor(s):	Arkenau-Maric; Elisabeth (Koln, DE), Bartholomaus; Johannes (Aachen, DE), Kugelmann; Heinrich (Aachen, DE)
Assignee:	Grunenthal GmbH (Aachen, DE)
Application Number:	13/270,505
Patent Claim Types: see list of patent claims	Compound; Dosage form; Process; Composition;

Drugs Protected by US Patent 8,420,056

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-001	Aug 25, 2011		RX	Yes	No			Y
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-002	Aug 25, 2011		RX	Yes	No			Y
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-003	Aug 25, 2011		RX	Yes	No			Y

International Family Members for US Patent 8,420,056

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	045352
Argentina	045353
Argentina	046994